The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Abstract
Treating patients who have cancer with vaccines that stimulate a targeted immune response is conceptually appealing, but cancer vaccine trials have not been successful in late-stage patients with treatment-refractory tumours 1,2. We are testing melanoma FixVac (BNT111)-an intravenously administered liposomal RNA (RNA-LPX) vaccine, which targets four non-mutated, tumour-associated antigens that are prevalent in melanoma-in an ongoing, first-in-human, dose-escalation phase I trial in patients with advanced melanoma (Lipo-MERIT trial, ClinicalTrials.gov identifier NCT02410733). We report here data from an exploratory interim analysis that show that melanoma FixVac, alone or in combination with blockade of the checkpoint inhibitor PD1, mediates durable objective responses in checkpoint-inhibitor (CPI)-experienced patients with unresectable melanoma. Clinical responses are accompanied by the induction of strong CD4+ and CD8+ T cell immunity against the vaccine antigens. The antigen-specific cytotoxic T-cell responses in some responders reach magnitudes typically reported for adoptive T-cell therapy, and are durable. Our findings indicate that RNA-LPX vaccination is a potent immunotherapy in patients with CPI-experienced melanoma, and suggest the general utility of non-mutant shared tumour antigens as targets for cancer vaccination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical trials of mRNA-based immunotherapeutics encoding unmutated full-length TAAs in checkpoint inhibitor-treated melanoma [18] and individualised mRNA-based immunotherapeutics encoding patient-specific mutated tumour neoantigens in pancreatic and lung cancer [19, 20] have shown encouraging results.”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [18]
In the citing paper
“Previous studies have demonstrated that the use of BNT111 alone or in combination with PD-1 antibody can activate tumor antigen-specific CD4+ and CD8+ T cells and elicit durable immune responses.345,350–352”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [345]
In the citing paper
“For example, FixVac, which was developed based on the RNA-LPX formulation, is a systemic mRNA vaccine encoding four non-mutated antigens of melanoma200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“After the eighth immunization, more than 75% of patients generated immune responses against at least one tumour-associated antigen, and CD8+ T cells played a major role in high-magnitude T cell responses200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“Moreover, a combination of FixVac/anti-programmed cell death protein 1 (PD1) antibody augmented the antitumour effect of FixVac, resulting in a >35% tumour regression rate in immune checkpoint inhibitor-experienced patients200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“The interim analysis from the phase I trial (NCT02410733) showed that the metabolic activity of the spleen increased post the sixth immunization, indicating targeted delivery of FixVac and activation of resident immune cells200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Self-citationSystemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Self-citationMiXCR: software for comprehensive adaptive immunity profiling
Bolotin, D. A., Poslavskii, S., Mitrophanov, I., Shugay, M., Mamedov, I. Z., Putintseva, E. V., & Chudakov, D. M. (2015) · Nature Methods · doi:10.1038/nmeth.3364 · Cited by 1,730
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A. A., Chen, Y., & Old, L. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1669 · Cited by 1,587
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
Cited by
Sorted by citations
Items 601–700 of 1,000
Schlattmann, D., Weber, B., Wyszynski, L., Schönhoff, M., & Haas, H. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114380 · Cited by 8
Self-citationFehn, A., Witzleben, A. V., Grages, A., Kors, T. A., Ezić, J., Betzler, A. C., Brunner, C., Schuler, P. J., Theodoraki, M., Hoffmann, T. K., et al. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101086 · Cited by 8
Cancer and COVID-19: On the Quest for Effective Vaccines
Kwok, M., Fritsch, E. F., & Wu, C. J. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0205 · Cited by 8
Martínez‐Cortés, F., Servín-Blanco, R., Domínguez‐Romero, A. N., Munguía, M. E., Valle, J. G., Odales, J., Gevorkian, G., & Manoutcharian, K. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.08.013 · Cited by 8
Position‐Scanning Peptide Libraries as Particle Immunogens for Improving CD8+ T‐Cell Responses
He, X., Zhou, S., Quinn, B., Huang, W., Jahagirdar, D., Vega, M., Ortega, J., Long, M. D., Ito, F., Abrams, S. I., et al. (2021) · Advanced Science · doi:10.1002/advs.202103023 · Cited by 8
TSAFinder: exhaustive tumor-specific antigen detection with RNAseq
Sharpnack, M. F., Johnson, T. S., Chalkley, R. J., Han, Z., Carbone, D. P., Huang, K., & He, K. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac116 · Cited by 8
mRNA—From COVID-19 Treatment to Cancer Immunotherapy
Kŕause, W. (2023) · Biomedicines · doi:10.3390/biomedicines11020308 · Cited by 8
Updated Considerations for the Immunopharmacological Aspects of the “Talented mRNA Vaccines”
Perrotta, C., Fenizia, C., Carnovale, C., Pozzi, M., Trabattoni, D., Cervia, D., & Clementi, E. (2023) · Vaccines · doi:10.3390/vaccines11091481 · Cited by 9
Salomon, N., Helm, A., Selmi, A., Fournier, C., Diken, M., Schrörs, B., Scholz, M., Kreiter, S., Durante, M., & Vascotto, F. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.12.042 · Cited by 7
Self-citationWang, Y., Hu, M., Finn, O. J., & Wang, X. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0932 · Cited by 7
Biocompatible lipid nanovehicles for preventive and therapeutic vaccine development
Jia, Y., Zhou, Z., Jiramonai, L., Chen, J., Hua, Q., Zhu, M., Zhang, J., & Liang, X. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216718 · Cited by 7
Shen, W., Hu, D., Gong, C., Cheng, F., Luo, J., Wang, L., Yao, C., Wu, H., Zhao, C., & Zhu, S. (2025) · Chinese Medicine · doi:10.1186/s13020-025-01134-w · Cited by 7
Global hotspots and trends in pre-metastatic niche research: a bibliometric analysis(2005-2024)
Cheng, M., Sun, Q., Duan, H., & Chen, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1552053 · Cited by 7
Deciphering the MHC immunopeptidome of human cancers with Ligand.MHC atlas
Ran, Z., Mu, M., Lin, S., Wang, T., Zeng, J., Kuang, L., Chen, K., Suo, S., Yuan, K., & Xu, H. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf314 · Cited by 8
Zhang, Y., Liu, J., Chang, X., Yang, X., Zhang, X., & Xiao, W. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01340-6 · Cited by 7
Lu, Z., Zhu, W., & Liu, X. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152399 · Cited by 9
Dang, B.-T. N., Pham, K., Nguyen, A.-H., Park, J., Kwon, T. K., Kang, J., Jeong, J., & Yook, S. (2025) · Biomaterials Research · doi:10.34133/bmr.0289 · Cited by 7
Tumorvakzinierung –Strategien und Timing
Maringer, Y., & Walz, J. S. (2021) · Der Internist · doi:10.1007/s00108-021-01138-2 · Cited by 7
Engineering programmable RNA synthetic circuits in mammalian cells
Cella, F., Martino, I. D., Piro, F. R., & Siciliano, V. (2021) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2021.100395 · Cited by 7
Current status of vaccine immunotherapy for gastrointestinal cancers
Suzuki, N., Shindo, Y., Nakajima, M., Tsunedomi, R., & Nagano, H. (2023) · Surgery Today · doi:10.1007/s00595-023-02773-y · Cited by 7
Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy
Eskandari, A., Leow, T. C., Rahman, M. B. A., & Oslan, S. N. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01144-3 · Cited by 7
Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma
Li, D., Andaloori, L., Crowe, M., Lin, S., Hong, J., Zaidi, N., & Ho, M. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.10.021 · Cited by 7
Enhanced Antitumor Immunity Through T Cell Activation with Optimized Tandem Double-OX40L mRNAs
Deng, Z., Tian, Y., Wang, J., Xu, Y., Liu, Z., Xiao, Z., Wang, Z., Hu, M., Liu, R., & Yang, P. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s479434 · Cited by 7
State-of-the-art review on liposomes as versatile cancer vaccine delivery systems
Vatankhah, A., Oroojalian, F., Moghaddam, S. H., Kesharwani, P., & Sahebkar, A. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106975 · Cited by 7
Wu, J., Yan, D., Du, X., Wu, C., Lin, X., Xu, B., Xu, Y. C., Ye, J., & Shen, Y. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.010 · Cited by 7
RetractedImmuno-oncology in triple-negative breast cancer
Heimes, A.-S., & Schmidt, M. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2020.124 · Cited by 7
Adhikary, K., Paul, A., Madan, A., Islam, A., Ashique, S., & Ramzan, M. (2025) · Advances in immunology · doi:10.1016/bs.ai.2024.10.011 · Cited by 6
Lei, S., Gao, Y., Wang, K., Wu, S., Zhu, M., Chen, X., Zhou, W., Chen, X., Zhang, J., Duan, X., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c01366 · Cited by 6
Nanoparticles engineering strategies for lymph-node targeted cancer immunotherapy
Chandpa, H. H., Gupta, A., Naskar, S., & Meena, J. (2025) · Nano Trends · doi:10.1016/j.nwnano.2025.100128 · Cited by 6
Designing nucleic acid-based therapeutics for cancer treatment: Updates on the state of the art
Peng, B., Jayasinghe, M. K., Le, A. H., Tran, N. M., & Le, M. T. N. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.041 · Cited by 7
Magoola, M., & Niazi, S. K. (2025) · Vaccines · doi:10.3390/vaccines13090970 · Cited by 7
Engineering Delivery Technologies for Optimizing mRNA Vaccines
Gu, T., Yan, X., & Liu, S. (2025) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00032 · Cited by 7
Evolution and trends in non-viral mRNA Cancer vaccines: A scoping review from 2015 to 2025
Nowzari, F., Nowzari, F., Kian, M., Zahedi, M., Samimi, K., Karimzadeh, A., Tanideh, N., Mussin, N. M., & Tamadon, A. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.128059 · Cited by 6
Harnessing RNA molecules for therapy: advances in design, delivery, and clinical development
Zou, J., He, X., Li, Z., Song, B., Xing, X., Yu, J., & He, W. (2025) · Targetome · doi:10.48130/targetome-0025-0003 · Cited by 7
Beyond the Sequence: Chemical and Topological Design and Innovations in mRNA Therapeutics
Liu, D., Chen, H., Pan, A., & Wang, X. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00347 · Cited by 7
Bright side of the dark genome: antigens for next-gen cancer vaccines
Wang, X., & Fox, B. A. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014075 · Cited by 6
Towards customized cancer vaccines: a promising filed in personalized cancer medicine
Xu, X., Zhou, Z., Li, H., & Fan, Y. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1909479 · Cited by 6
Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises
Ashi, M. O., Mami‐Chouaib, F., & Corgnac, S. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00111 · Cited by 7
Therapeutic cancer vaccination against telomerase: clinical developments in melanoma
Ellingsen, E. B., Bjørheim, J., & Gaudernack, G. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000922 · Cited by 6
Antigenic targets in clear cell renal cell carcinoma
Schindler, N. R., & Braun, D. A. (2023) · Kidney Cancer · doi:10.3233/kca-230006 · Cited by 6
Immunotherapy for mucosal melanoma
Du, Y., Bai, X. L., & Si, L. (2023) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000019 · Cited by 7
Refining mutanome-based individualised immunotherapy of melanoma using artificial intelligence
Zakariya, F., Salem, F. K., Alamrain, A. A., Sanker, V., Abdelazeem, Z. G., Hosameldin, M., Tan, J. K., Howard, R., Huang, H. Y. R., & Awuah, W. A. (2024) · European journal of medical research · doi:10.1186/s40001-023-01625-2 · Cited by 6
Unlocking cancer vaccine potential: What are the key factors?
Grant, M. D., Lee, L. N., Chinnakannan, S. K., Tong, O., Kwok, J., Cianci, N., Tillman, L., Saha, A., Almeida, V. P., & Leung, C. S. K. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2331486 · Cited by 6
Unlocking Immunity: Innovative prostate cancer vaccine strategies
Gu, Q., Qi, A., Wang, N., Zhou, Z., & Zhou, X. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113137 · Cited by 7
Novel vaccines against lung cancer
Baka, S., Iraklis, G., & Papadopoulou, E. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001102 · Cited by 7
RNA-lipid nanoparticle therapeutics for women’s health
Nomani, A., Saraswat, A. L., Zhang, Y., Parenky, A. C., Kuo, C.-T. J., Brown, H., Hartford, S. A., Rayaprolu, B. M., Bhalla, A. S. B., & Shameem, M. (2025) · Frontiers in Nanotechnology · doi:10.3389/fnano.2025.1475969 · Cited by 7
Zhang, H., Ma, J., Pan, F., Liu, Y., Zhang, M., Li, Y., Zhang, C., Huang, H., Zhang, W., Xiu, D., et al. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01217a · Cited by 6
Beyond Ipilimumab: a review of immunotherapeutic approaches in clinical trials in melanoma
Middleton, G. (2020) · Immunotherapy Advances · doi:10.1093/immadv/ltaa010 · Cited by 6
Delivery Systems of Plasmid DNA and Messenger RNA for Advanced Therapies
Uchida, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040810 · Cited by 6
Guelman, S. A., Zhou, Y., Brady, A. C., & Peng, K. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00709-x · Cited by 6
Human Papillomavirus–Directed Therapeutics for Human Papillomavirus–Associated Oropharyngeal Cancer
Campbell, J. S., & Pai, S. I. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000621 · Cited by 6
Thelen, M., Keller, D. T., Lehmann, J. M., Wennhold, K., Weitz, H., Bauer, E., Gathof, B. S., Brüggemann, M., Kotrová, M., Quaas, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005200 · Cited by 6
Unlocking Delivery Strategies for mRNA Therapeutics
Luo, Z., & Chen, Y. (2023) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892818666230607093231 · Cited by 6
APR-246 increases tumor antigenicity independent of p53
Michels, J., Venkatesh, D., Liu, C., Budhu, S., Zhong, H., George, M. M., Thach, D., Yao, Z., Ouerfelli, O., Liu, H., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202301999 · Cited by 6
Immunogenicity of Non-Mutated Ovarian Cancer-Specific Antigens
Hesnard, L., Thériault, C., Cahuzac, M., Durette, C., Vincent, K., Hardy, M., Lanoix, J., Lavallée, G. O., Humeau, J. F., Thibault, P., et al. (2024) · Current Oncology · doi:10.3390/curroncol31060236 · Cited by 6
Computational Quantification of Cancer Immunoediting
Liu, K., He, S., Sun, S., Zhang, X., He, Y., Quan, F., Pang, B., & Xiao, Y. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0926 · Cited by 6
mRNA-Based Nanomedicine: A New Strategy for Treating Infectious Diseases and Beyond
Prakash, S. (2023) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-023-00849-1 · Cited by 6
Editorial: mRNA Vaccines and Immunotherapy in Oncology: A New Era for Personalized Medicine
Parums, D. V. (2021) · Medical Science Monitor · doi:10.12659/msm.933088 · Cited by 6
RetractedDang, W., Cui, T., Jiao, G., Li, J., & Liu, Z. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107261 · Cited by 5
Unraveling the potential: mRNA therapeutics in oncology
Gawalski, K., Przybyszewska, W., Hunia, J., Gawalska, A., & Rymarz, A. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1643444 · Cited by 6
Messenger RNA and Plasmid DNA Vaccines for the Treatment of Cancer
Moseman, J. E., Shim, D., Jeon, D., Rastogi, I., Schneider, K. M., & McNeel, D. G. (2025) · Vaccines · doi:10.3390/vaccines13090976 · Cited by 5
Li, F., Wang, D., Gao, Y., & Cui, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1648698 · Cited by 6
Targeting strategies, clinical translation and translational barriers of liposomes in cancer therapy
Su, J., Na, J., Yang, Q., Huang, H., Xiao, L., Wu, P., & Zhong, L. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.153155 · Cited by 7
The Recent Research Progress of the Tumor mRNA Vaccine
Zhao, H., Li, M., Zhou, J., Hu, L., Lu, S., & Li, P. (2024) · Vaccines · doi:10.3390/vaccines12101167 · Cited by 5
Insights for the immunotherapy in malignant melanoma: a new revolution
Xuan, J., Gao, Z., Wei, C., & Gu, J. (2024) · Clinical Cancer Bulletin · doi:10.1007/s44272-024-00026-8 · Cited by 5
Cholic acid-mediated targeting of mRNA-LNPs improve the mRNA delivery to Caco-2 cells
Shinkai, T., Ogawa, K., Tagami, T., & Ozeki, T. (2024) · Journal of Nanoparticle Research · doi:10.1007/s11051-024-06161-6 · Cited by 5
Janes, L. A., Haykal, T., & Angeles, C. V. (2025) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.01.004 · Cited by 5
Fereidouni, M., Roointanpour, Y., Movahed, H., Taghipour, A., Vafafar, A., & Jahromi, M. A. M. (2025) · Discover Applied Sciences · doi:10.1007/s42452-025-06998-z · Cited by 5
Peng, S., Hou, F., Yang, X., Wang, W., Li, X., Tang, Y., Chen, Y., Yang, C., & Li, X. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125785 · Cited by 6
Yong, S., Ha, M., & Cho, S. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c00738 · Cited by 5
Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients
Broderick, J. C., Adams, A. M., Barbera, E. L., Decar, S. G. V., Clifton, G. T., & Peoples, G. E. (2025) · Vaccines · doi:10.3390/vaccines13060656 · Cited by 5
Tumor immunotherapy: past, present, and future
Huang, Y., Ge, H., Zhang, Z., Liu, X., Zhong, K., Tong, A., Li, G., & Zhou, L. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002919 · Cited by 6
Meade, E., & Garvey, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178307 · Cited by 5
An RNA vaccine for advanced melanoma
Bordon, Y. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00145-6 · Cited by 5
Iodine-124 PET quantification of organ-specific delivery and expression of NIS-encoding RNA
Miederer, M., Pektor, S., Miederer, I., Bausbacher, N., Keil, I. S., Hefesha, H., Haas, H., Şahin, U., & Diken, M. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00753-2 · Cited by 5
Self-citationVaccines as Priming Tools for T Cell Therapy for Epithelial Cancers
Kandalaft, L. E., & Harari, A. (2021) · Cancers · doi:10.3390/cancers13225819 · Cited by 6
Ferrari, V., Stroobant, V., Habib, J. A., Naulaerts, S., den Eynde, B. J. V., & Vigneron, N. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2101198 · Cited by 5
Cao, X., Zhou, X., Chen, C., Wang, Z., & Sun, Q. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.962389 · Cited by 5
Synthetic Melanin Acts as Efficient Peptide Carrier in Cancer Vaccine Strategy
Cuzzubbo, S., Roch, B., Darrasse-Jèze, G., Hosten, B., Leclercq, M., Vignal, N., Banissi, C., Tartour, É., & Carpentier, A. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314975 · Cited by 5
Metal Nanoparticles: Synthesis, Characterization, and Biomedical Applications
Putta, S., Sharma, R. K., & Khandelwal, P. (2023) · Springer eBooks · doi:10.1007/978-981-19-7963-7_4 · Cited by 5
Pathogen Recognition-Driven Dendritic Cell-Specific Gene Silencing and Editing
Li, M., Zhou, H., Wu, N., Deng, W., Wang, D., Sun, X., Liu, H., Tian, Z., & Wang, Y. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c00015 · Cited by 5
Wojtczak, B. A., Bednarczyk, M., Sikorski, P. J., Wojtczak, A., Surynt, P., Kowalska, J., & Jemielity, J. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c00126 · Cited by 5
Transcriptome analysis reveals tumor antigen and immune subtypes of melanoma
Xie, J., Ou, M., YU, P., Wu, D., Tang, Q., Cao, Y., Hang, J., YIN, L., Xiang, T., WANG, M., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.029274 · Cited by 5
Wang, X., Jia, Q., Wu, M., Liu, M., & Li, J. (2023) · Vaccines · doi:10.3390/vaccines11061113 · Cited by 5
Younis, M. A., & Harashima, H. (2024) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s431346 · Cited by 7
Song, L., Yang, Y., & Tian, X. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2023.150 · Cited by 5
IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines
Sobral, M. C., Cabizzosu, L., Kang, S. J., Ruark, K. T., Najibi, A. J., Lane, R. S., Vitner, E. B., Ijaz, H., Dellacherie, M. O., Dacus, M. T., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322356121 · Cited by 5
Niazi, S. K., & Magoola, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312797 · Cited by 5
Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
Lloyd, K. A., Middelburg, J., Ovcinnikovs, V., Pencheva, N., Kemper, K., & van Hall, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1548446 · Cited by 5
Chasing neoantigens; invite naïve T cells to the party
Bollineni, R. C., Tran, T. T., Lund‐Johansen, F., & Olweus, J. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102172 · Cited by 5
Cancer vaccine induces potent T cell responses — but is it enough?
Rohatgi, A., & Kirkwood, J. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00437-1 · Cited by 5
Editorial: Nanomedicine in Cancer Targeting and Therapy
Longo, J. P. F., Muehlmann, L. A., Calderón, M., Stockmann, C., & Azevedo, R. B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.788210 · Cited by 5
A extrafiscalidade e os controles de proporcionalidade e de igualdade
Papadopol, M. D. (2009) · Americanae (AECID Library) · Cited by 5
A Historical Overview on mRNA Vaccine Development
Verbeke, R., Cheng, M. H. Y., & Cullis, P. R. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch1 · Cited by 5
Progress on Synthetic Genomics
Abdi, G., Firdous, S., Vasantharekha, R., Singh, G. B., Seetharaman, B., Mudgal, G., Jain, M., & Tarighat, M. A. (2024) · Springer eBooks · doi:10.1007/978-981-97-3169-5_9 · Cited by 4
The therapeutic effect of mRNA vaccines in glioma: a comprehensive review
Afrashteh, F., Seyedpour, S., & Rezaei, N. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2494656 · Cited by 4
Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms
Pazoki, A., Dadfar, S., Alirezaee, A., Oksenych, V., & Haghmorad, D. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1617352 · Cited by 4
Research and Clinical Progress of Therapeutic Tumor Vaccines
Dong, C., Zhuang, L., Tan, D., Sun, H., Liang, J., Wei, D., Zheng, Y., Zhang, L., Liu, S., Zhang, Y., et al. (2025) · Vaccines · doi:10.3390/vaccines13070672 · Cited by 5
Grigoruţă, M., Kong, X., & Qin, Y. W. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145137 · Cited by 4
Muscle-targeting LNP vaccines enable potent immune responses against varicella zoster virus
Zhang, H., Ma, J., Jin, L., Ma, Y., Dong, K., Li, J., Yu, F., & Song, G. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01961-2 · Cited by 4
Metadata
- Authors
- Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., Kranz, L. M., Diken, M., Kreiter, S., Haas, H., Attig, S., Rae, R., Cuk, K., Kemmer-Brück, A., Breitkreuz, A., Tolliver, C., Caspar, J., Quinkhardt, J., Hebich, L., Stein, M., Hohberger, A., Vogler, I., Liebig, I., Renken, S., Sikorski, J., Leierer, M., Müller, V., Mitzel-Rink, H., Miederer, M., Huber, C., Grabbe, S., Utikal, J., Pinter, A., Kaufmann, R., Hassel, J. C., Loquai, C., & Türeci, Ö.
- Affiliations
- BioNTech (Germany) (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- German Cancer Research Center (DE)
- University Hospital Frankfurt (DE)
- ORCID
- Venue
- Nature
- Published
- 2020-07-29
- Volume
- 585
- Issue
- 7823
- Pages
- 107-112
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3046115489
- Cited by
- 1,052
- References
- 36
- Citations by year
- 2026: 140 · 2025: 204 · 2024: 191 · 2023: 190 · 2022: 174 · 2021: 131 · 2020: 21
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- RNA vaccines, melanoma, anti-PD-1 therapy, immune checkpoint inhibitors, tumor-associated antigens, cancer immunotherapy, CD4+ T cells, CD8+ T cells, cytotoxic T lymphocyte response
- MeSH terms
- Antigens, Neoplasm, Antineoplastic Agents, Combined Modality Therapy, Humans, Melanoma, Neoplasm Staging, RNA, Neoplasm, T-Lymphocytes, T-Lymphocytes, Cytotoxic, Vaccination, Cancer Vaccines, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
